| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Passage BIO, Inc.
13D
PASG · 702712100
|
21.0% |
7/2/2026
Event 6/25/2026
|
||||
| Lynx1 Capital Management LP | 21.0% | |||||
| Weston Nichols | 21.0% | |||||
|
Neuphoria Therapeutics Inc.
13D/A
NEUP · 64136E102
|
16.3% |
12/29/2025
Event 12/26/2025
|
||||
| Lynx1 Capital Management LP | 16.3% | |||||
| Weston Nichols | 16.3% | |||||
| Schedule 13G · 10 securities · passive | ||||||
|
Precision BioSciences, Inc.
13G/A
DTIL · 74019P207
|
9.9% |
11/16/2026
Event 9/30/2026
|
||||
| Lynx1 Capital Management LP | 9.9% | |||||
| Weston Nichols | 9.9% | |||||
|
Agios Pharmaceuticals, Inc.
13G/A
AGIO · 00847X104
|
0.8% |
11/16/2026
Event 9/30/2026
|
||||
| Lynx1 Capital Management LP | 0.8% | |||||
| Weston Nichols | 0.8% | |||||
|
TScan Therapeutics, Inc.
13G/A
TCRX · 89854M101
|
13.1% |
8/14/2026
Event 6/30/2026
|
||||
| Lynx1 Capital Management LP | 13.1% | |||||
| Weston Nichols | 13.1% | |||||
|
Stoke Therapeutics, Inc.
13G/A
STOK · 86150R107
|
6.5% |
8/14/2026
Event 6/30/2026
|
||||
| Lynx1 Capital Management LP | 6.5% | |||||
| Weston Nichols | 6.5% | |||||
|
C4 Therapeutics, Inc.
13G/A
CCCC · 12529R107
|
10.0% |
8/14/2026
Event 6/30/2026
|
||||
| Lynx1 Capital Management LP | 10.0% | |||||
| Weston Nichols | 10.0% | |||||
|
iBio, Inc.
13G
IBIO · 451033708
|
5.4% |
8/14/2026
Event 6/30/2026
|
||||
| Lynx1 Capital Management LP | 5.4% | |||||
| Weston Nichols | 5.4% | |||||
|
GH Research PLC
13G/A
GHRS · G3855L106
|
19.3% |
8/14/2026
Event 6/30/2026
|
||||
| Lynx1 Capital Management LP | 19.3% | |||||
| Weston Nichols | 19.3% | |||||
|
Allogene Therapeutics, Inc.
13G/A
ALLO · 019770106
|
0% |
5/15/2026
Event 12/31/2025
|
||||
| Lynx1 Capital Management LP | 0% | |||||
| Weston Nichols | 0% | |||||
|
Korro Bio, Inc.
13G/A
KRRO · 500946108
|
10.7% |
4/2/2026
Event 3/31/2026
|
||||
| Lynx1 Capital Management LP | 10.7% | |||||
| Weston Nichols | 10.7% | |||||
|
Cullinan Therapeutics, Inc.
13G/A
CGEM · 230031106
|
9.8% |
11/14/2025
Event 9/30/2025
|
||||
| LYNX1 Capital Management LP | 9.8% | |||||
| Weston Nichols | 9.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.